ASPirin in Immune thRombocytopenia patients with cardiovascular disEase - ASPIRE

CHU Toulouse0 个研究点目标入组 10 人开始时间: 2021年3月2日最近更新: 2024年6月3日

适应症

试验速览

暂无简介。

•adult patients (sup 18-year-old); non-treated ITP or ITP with stable treatment (at least 1 month); treated with aspirin daily for a cardiovascular disease; stable platelet count < 100 x 109/L; at least one month following an arterial thrombosis; no other antiplatelet drug and anticoagulant; affiliated or benefiting from public health insurance.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•opposition to participate; modification of ITP treatment, NSAID, serotonin reuptake inhibitor, antiplatelet or anticoagulant drug initiation during the study period; platelet count ?100 x 109/L at visit 1 or 2; CRP>10 mg/L at visit 1 or 2, adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision. Pregnancy or breastfeeding.

发起方

CHU Toulouse